| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Division of Medical Sciences, Queen Elizabeth Hospital, University of Birmingham (J.W.T., J.M., M.S.C., I.B., M.H., P.M.S.), Birmingham, United Kingdom B15 2TH; Department of Genitourinary Medicine, Selly Oak Hospital (M.S.), Birmingham, United Kingdom B29 6JD; Department of Hepatology, Queen Elizabeth Hospital, University of Birmingham (C.S., A.S.), United Kingdom B15 2TH
Address all correspondence and requests for reprints to: Prof. P. M. Stewart, M.D., F.R.C.P., F.Med.Sci. Division of Medical Sciences, University of Birmingham, Queen Elizabeth Hospital, Birmingham, United Kingdom B15 2TH. E-mail: p.m.stewart{at}bham.ac.uk
Patients with glucocorticoid excess develop central obesity, yet in simple obesity, circulating glucocorticoid levels are normal. We have suggested that the increased activity and expression of the enzyme 11ß-hydroxysteroid dehydrogenase type 1 (11ßHSD1) generating active cortisol from cortisone within adipose tissue may be crucial in the pathogenesis of obesity. In this study primary cultures of human hepatocytes and adipose stromal cells (ASC) were used as in vitro models to investigate the tissue-specific regulation of 11ßHSD1 expression and activity.
Treatment with tumor necrosis factor-
(TNF) caused a
dose-dependent increase in 11ßHSD1 activity in primary cultures of
both sc [1743.1 ± 1015.4% (TNF, 10 ng/ml);
P < 0.05 vs. control (100%)] and
omental [375.8 ± 57.0% (TNF, 10 ng/ml);
P < 0.01 vs. control (100%)] ASC,
but had no effect on activity in human hepatocytes [90.2 ± 2.8%
(TNF, 10 ng/ml); P = NS vs.
control (100%)]. Insulin-like growth factor I (IGF-I) caused a
dose-dependent inhibition of 11ßHSD1 activity in sc [49.7 ±
15.0% (IGF-I, 100 ng/ml]; P < 0.05
vs. control (100%)] and omental [71.6 ± 7.5
(IGF-I, 100 ng/ml); P < 0.01 vs.
control (100%)] stromal cells, but not in human hepatocytes
[101.8 ± 15.7% (IGF-I, 100 ng/ml); P = NS
vs. control (100%)]. Leptin treatment did not alter
11ßHSD1 activity in human hepatocytes, but increased activity in
omental ASC [135.8 ± 14.1% (leptin, 100 ng/ml);
P = 0.08 vs. control (100%)].
Treatment with interleukin-1ß induced 11ßHSD1 activity and
expression in sc and omental ASC in a time- and dose-dependent manner.
15-Deoxy-
12,14-PGJ2, the putative endogenous ligand of the orphan
nuclear receptor peroxisome proliferator-
, significantly increased
11ßHSD1 activity in omental cells [179.7 ± 29.6% (1
µM); P < 0.05 vs.
control (100%)] and sc [185.3 ± 12.6% (1 µM);
P < 0.01 vs. control (100%)] ASC,
and it is possible that expression of this ligand may ensure continued
cortisol generation to permit adipocyte differentiation. Protease
inhibitors used in the treatment of human immunodeficiency virus
infection are known to cause a lipodystrophic syndrome and central
obesity, but saquinavir, indinavir, and neflinavir caused a
dose-dependent inhibition of 11ßHSD1 activity in primary cultures of
human omental ASC.
11ßHSD1 expression is increased in human adipose tissue by
TNF, interleukin-1ß, leptin, and orphan nuclear receptor
peroxisome proliferator- agonists, but is inhibited by IGF-I. This
autocrine and/or paracrine regulation is tissue specific and explains
recent clinical data and animal studies evaluating cortisol metabolism
in obesity. Tissue-specific 11ßHSD1 regulation offers the potential
for selective enzyme inhibition within adipose tissue as a novel
therapy for visceral obesity.
This article has been cited by other articles:
 |
|
 |
|
  R Hardy and M S Cooper Bone loss in inflammatory disorders J. Endocrinol., June 1, 2009; 201(3): 309 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Jang, V. R Obeyesekere, F. P Alford, and W. J Inder Skeletal muscle 11{beta} hydroxysteroid dehydrogenase type 1 activity is upregulated following elective abdominal surgery Eur. J. Endocrinol., February 1, 2009; 160(2): 249 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. D. Ignatova, R. M. Kostadinova, C. E. Goldring, A. R. Nawrocki, F. J. Frey, and B. M. Frey Tumor necrosis factor-{alpha} upregulates 11{beta}-hydroxysteroid dehydrogenase type 1 expression by CCAAT/enhancer binding protein-{beta} in HepG2 cells Am J Physiol Endocrinol Metab, February 1, 2009; 296(2): E367 - E377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Marik Critical Illness-Related Corticosteroid Insufficiency Chest, January 1, 2009; 135(1): 181 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Yang, P. Zhu, C. Guo, X. Zhu, and K. Sun Expression of 11{beta}-Hydroxysteroid Dehydrogenase Type 1 in Human Fetal Lung and Regulation of Its Expression by Interleukin-1{beta} and Cortisol J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 306 - 313. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Boullu-Ciocca, V. Achard, V. Tassistro, A. Dutour, and M. Grino Postnatal Programming of Glucocorticoid Metabolism in Rats Modulates High-Fat Diet-Induced Regulation of Visceral Adipose Tissue Glucocorticoid Exposure and Sensitivity and Adiponectin and Proinflammatory Adipokines Gene Expression in Adulthood Diabetes, March 1, 2008; 57(3): 669 - 677. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K S Fegan, M T Rae, H O D Critchley, and S G Hillier Anti-inflammatory steroid signalling in the human peritoneum J. Endocrinol., February 1, 2008; 196(2): 369 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G Hillier Diamonds are forever: the cortisone legacy J. Endocrinol., October 1, 2007; 195(1): 1 - 6. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Buren, S.-A. Bergstrom, E. Loh, I. Soderstrom, T. Olsson, and C. Mattsson Hippocampal 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Messenger Ribonucleic Acid Expression Has a Diurnal Variability that Is Lost in the Obese Zucker Rat Endocrinology, June 1, 2007; 148(6): 2716 - 2722. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Tomlinson, M. Sherlock, B. Hughes, S. V. Hughes, F. Kilvington, W. Bartlett, R. Courtney, P. Rejto, W. Carley, and P. M. Stewart Inhibition of 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Activity in Vivo Limits Glucocorticoid Exposure to Human Adipose Tissue and Decreases Lipolysis J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 857 - 864. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. J Bujalska, O. M Durrani, J. Abbott, C. U Onyimba, P. Khosla, A. H Moosavi, T. T Q Reuser, P. M Stewart, J. W Tomlinson, E. A Walker, et al. Characterisation of 11{beta}-hydroxysteroid dehydrogenase 1 in human orbital adipose tissue: a comparison with subcutaneous and omental fat J. Endocrinol., February 1, 2007; 192(2): 279 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Dover, P. W. F. Hadoke, L. J. Macdonald, E. Miller, D. E. Newby, and B. R. Walker Intravascular Glucocorticoid Metabolism during Inflammation and Injury in Mice Endocrinology, January 1, 2007; 148(1): 166 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K Vagnerova, M Kverka, P Klusonova, P Ergang, I Miksik, H Tlaskalova-Hogenova, and J Pacha Intestinal inflammation modulates expression of 11{beta}-hydroxysteroid dehydrogenase in murine gut. J. Endocrinol., November 1, 2006; 191(2): 497 - 503. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I J Bujalska, M Quinkler, J W Tomlinson, C T Montague, D M Smith, and P M Stewart Expression profiling of 11{beta}-hydroxysteroid dehydrogenase type-1 and glucocorticoid-target genes in subcutaneous and omental human preadipocytes. J. Mol. Endocrinol., October 1, 2006; 37(2): 327 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Mariniello, V. Ronconi, S. Rilli, P. Bernante, M. Boscaro, F. Mantero, and G. Giacchetti Adipose tissue 11{beta}-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome Eur. J. Endocrinol., September 1, 2006; 155(3): 435 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Arlt, F. Hammer, P. Sanning, S. K. Butcher, J. M. Lord, B. Allolio, D. Annane, and P. M. Stewart Dissociation of Serum Dehydroepiandrosterone and Dehydroepiandrosterone Sulfate in Septic Shock J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2548 - 2554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Grun and B. Blumberg Environmental Obesogens: Organotins and Endocrine Disruption via Nuclear Receptor Signaling Endocrinology, June 1, 2006; 147(6): s50 - s55. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bruley, V. Lyons, A. G. F. Worsley, M. D. Wilde, G. D. Darlington, N. M. Morton, J. R. Seckl, and K. E. Chapman A Novel Promoter for the 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Gene Is Active in Lung and Is C/EBP{alpha} Independent Endocrinology, June 1, 2006; 147(6): 2879 - 2885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Paulsen, S. B. Pedersen, J. O. L. Jorgensen, S. Fisker, J. S. Christiansen, A. Flyvbjerg, and B. Richelsen Growth Hormone (GH) Substitution in GH-Deficient Patients Inhibits 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Messenger Ribonucleic Acid Expression in Adipose Tissue J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 1093 - 1098. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J A P Da Silva, J W G Jacobs, J R Kirwan, M Boers, K G Saag, L B S Ines, E J P de Koning, F Buttgereit, M Cutolo, H Capell, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data Ann Rheum Dis, March 1, 2006; 65(3): 285 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Gnanalingham, A. Mostyn, R. Webb, D. H. Keisler, N. Raver, M. C. Alves-Guerra, C. Pecqueur, B. Miroux, M. E. Symonds, and T. Stephenson Differential effects of leptin administration on the abundance of UCP2 and glucocorticoid action during neonatal development Am J Physiol Endocrinol Metab, December 1, 2005; 289(6): E1093 - E1100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. C. Sandeep, R. Andrew, N. Z.M. Homer, R. C. Andrews, K. Smith, and B. R. Walker Increased In Vivo Regeneration of Cortisol in Adipose Tissue in Human Obesity and Effects of the 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Inhibitor Carbenoxolone Diabetes, March 1, 2005; 54(3): 872 - 879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Tomlinson, E. A. Walker, I. J. Bujalska, N. Draper, G. G. Lavery, M. S. Cooper, M. Hewison, and P. M. Stewart 11{beta}-Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid Response Endocr. Rev., October 1, 2004; 25(5): 831 - 866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bluher, M.-E. Patti, S. Gesta, B. B. Kahn, and C. R. Kahn Intrinsic Heterogeneity in Adipose Tissue of Fat-specific Insulin Receptor Knock-out Mice Is Associated with Differences in Patterns of Gene Expression J. Biol. Chem., July 23, 2004; 279(30): 31891 - 31901. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Tomlinson, J. S. Moore, P. M. S. Clark, G. Holder, L. Shakespeare, and P. M. Stewart Weight Loss Increases 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Expression in Human Adipose Tissue J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2711 - 2716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Morton, J. M. Paterson, H. Masuzaki, M. C. Holmes, B. Staels, C. Fievet, B. R. Walker, J. S. Flier, J. J. Mullins, and J. R. Seckl Novel Adipose Tissue-Mediated Resistance to Diet-Induced Visceral Obesity in 11{beta}-Hydroxysteroid Dehydrogenase Type 1-Deficient Mice Diabetes, April 1, 2004; 53(4): 931 - 938. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Justesen, L. Mosekilde, M. Holmes, K. Stenderup, J. Gasser, J. J. Mullins, J. R. Seckl, and M. Kassem Mice Deficient in 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Lack Bone Marrow Adipocytes, but Maintain Normal Bone Formation Endocrinology, April 1, 2004; 145(4): 1916 - 1925. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Seckl, N. M. Morton, K. E. Chapman, and B. R. Walker Glucocorticoids and 11beta-Hydroxysteroid Dehydrogenase in Adipose Tissue Recent Prog. Horm. Res., January 1, 2004; 59(1): 359 - 393. [Abstract] [Full Text]
|
|
|
|
|
|
K. Sun and L. Myatt Enhancement of Glucocorticoid-Induced 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Expression by Proinflammatory Cytokines in Cultured Human Amnion Fibroblasts Endocrinology, December 1, 2003; 144(12): 5568 - 5577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Cooper, A. Blumsohn, P. E. Goddard, W. A. Bartlett, C. H. Shackleton, R. Eastell, M. Hewison, and P. M. Stewart 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Activity Predicts the Effects of Glucocorticoids on Bone J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3874 - 3877. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Wake, E. Rask, D. E. W. Livingstone, S. Soderberg, T. Olsson, and B. R. Walker Local and Systemic Impact of Transcriptional Up-Regulation of 11{beta}-Hydroxysteroid Dehydrogenase Type 1 in Adipose Tissue in Human Obesity J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3983 - 3988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Lindsay, D. J. Wake, S. Nair, J. Bunt, D. E. W. Livingstone, P. A. Permana, P. A. Tataranni, and B. R. Walker Subcutaneous Adipose 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Activity and Messenger Ribonucleic Acid Levels Are Associated with Adiposity and Insulinemia in Pima Indians and Caucasians J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2738 - 2744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Tomlinson, N. Crabtree, P. M. S. Clark, G. Holder, A. A. Toogood, C. H. L. Shackleton, and P. M. Stewart Low-Dose Growth Hormone Inhibits 11{beta}-Hydroxysteroid Dehydrogenase Type 1 but Has No Effect upon Fat Mass in Patients with Simple Obesity J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2113 - 2118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. W. Livingstone and B. R. Walker Is 11beta -Hydroxysteroid Dehydrogenase Type 1 a Therapeutic Target? Effects of Carbenoxolone in Lean and Obese Zucker Rats J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 167 - 172. [Abstract] [Full Text]
|
|
|
|
|
|
M. Friedberg, E. Zoumakis, N. Hiroi, T. Bader, G. P. Chrousos, and Z.'e. Hochberg Modulation of 11{beta}-Hydroxysteroid Dehydrogenase Type 1 in Mature Human Subcutaneous Adipocytes by Hypothalamic Messengers J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 385 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Andrews, O. Herlihy, D. E. W. Livingstone, R. Andrew, and B. R. Walker Abnormal Cortisol Metabolism and Tissue Sensitivity to Cortisol in Patients with Glucose Intolerance J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5587 - 5593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Tomlinson, B. Sinha, I. Bujalska, M. Hewison, and P. M. Stewart Expression of 11{beta}-Hydroxysteroid Dehydrogenase Type 1 in Adipose Tissue Is Not Increased in Human Obesity J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5630 - 5635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Draper, S. M. Echwald, G. G. Lavery, E. A. Walker, R. Fraser, E. Davies, T. I. A. Sorensen, A. Astrup, J. Adamski, M. Hewison, et al. Association Studies between Microsatellite Markers within the Gene Encoding Human 11{beta}-Hydroxysteroid Dehydrogenase Type 1 and Body Mass Index, Waist to Hip Ratio, and Glucocorticoid Metabolism J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 4984 - 4990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Stulnig, U. Oppermann, K. R. Steffensen, G. U. Schuster, and J.-A. Gustafsson Liver X Receptors Downregulate 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Expression and Activity Diabetes, August 1, 2002; 51(8): 2426 - 2433. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
